Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination With Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

NCT02656303 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT02656303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02656303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination With Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 7, 2016
Completion date
July 11, 2022
Enrollment
116 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia